Phaseline

Targets › SDCL2

SDCL2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: the race on SDCL2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Henlius BiotechHLX15-SC
anti-CD38 monoclonal antibody
SDCL2Phase 1Multiple Myeloma (MM)May 2027

Conditions

Multiple Myeloma (MM) (1)

Modalities

small molecule (1)

Companies

Shanghai Henlius Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.